Amy Burroughs wird zur CEO von Terns Pharmaceuticals ernannt, nachdem sie zuvor Cleave Pharmaceuticals geleitet hatte. Amy Burroughs appointed as Terns Pharmaceuticals CEO after leading Cleave Pharmaceuticals.

Terns Pharmaceuticals hat Amy Burroughs zur neuen Chief Executive Officer ernannt. Terns Pharmaceuticals has appointed Amy Burroughs as its new Chief Executive Officer. Burroughs, der zuvor bei Cleave Pharmaceuticals und Crinetics Pharmaceuticals gearbeitet hat, wird ebenfalls dem Vorstand von Terns beitreten. Burroughs, who previously worked at Cleave Pharmaceuticals and Crinetics Pharmaceuticals, will also join Terns' board of directors. Von April 2019 bis Oktober 2023 war sie CEO von Cleave Pharmaceuticals. She served as the CEO of Cleave Pharmaceuticals from April 2019 to October 2023. Diese Ernennung folgt den jüngsten Erfolgen von Terns bei der Entwicklung eines Portfolios niedermolekularer Produktkandidaten zur Behandlung schwerwiegender Krankheiten wie Onkologie und Fettleibigkeit. This appointment follows Terns' recent achievements in developing a portfolio of small-molecule product candidates to address serious diseases, such as oncology and obesity.